Lysophosphatidic acid enhances stromal cell-directed angiogenesis

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Biochemistry

Background:

• Ischemic diseases like peripheral vascular disease (PVD) affect over 15% of the population, leading to severe complications including limb loss.
• Current therapeutic angiogenesis strategies using recombinant growth factors are limited by high costs and delivery challenges.
• Multipotent adipose-derived stromal cells (ASC) offer a promising cell-based alternative for delivering angiogenic factors.

Purpose of the Study:

• To investigate the synergistic effects of lysophosphatidic acid (LPA) and ASC on therapeutic angiogenesis.
• To evaluate the potential of LPA-ASC combination therapy for treating ischemic conditions.

Main Methods:

• ASC were cultured under serum deprivation and hypoxia (SD/H) conditions with and without LPA.
• The proangiogenic factor production by ASC and their effect on endothelial cell migration were assessed in vitro.
• The efficacy of concurrent LPA and ASC delivery in fibrin gels was evaluated in a murine critical hindlimb ischemia model.

Main Results:

• LPA significantly upregulated the production of angiogenic growth factors by ASC under SD/H conditions.
• These LPA-induced factors enhanced endothelial cell migration.
• Concurrent delivery of LPA and ASC in fibrin gels markedly improved vascularization in a murine hindlimb ischemia model compared to either treatment alone.

Conclusions:

• LPA synergistically enhances the proangiogenic capacity of ASC, offering a novel and cost-effective approach for therapeutic angiogenesis.
• This LPA-ASC combination strategy demonstrates significant translational potential for treating ischemic diseases and preventing tissue damage.